Prevacus has announced that it plans to initiate a Phase 1 clinical trial of its PRV-002 intranasal product for the treatment of mild traumatic brain injury (mTBI) by the middle of 2017.
According to the company, pre-clinical studies showed that intranasal administration of PRV-002 positively impacted memory, sensory-motor function, cerebral edema, anxiety and other factors associated with concussion.
Prevacus CEO Jake VanLandingham said, “I am excited with the progress we’ve made in advancing PRV-002, our novel treatment for mTBI. Concussion presents a significant, unmet medical need, and our PRV-002 compound has the potential to reduce the adverse effects associated with mTBI in athletes, military personnel, and civilian patients while improving the quality of life thereby, saving the U.S. Healthcare system significant costs.”
Read the Prevacus press release.
